Vivos Inc. (RDGL)

0.1850 -0.0147 (-7.36%) At close: 03:59PM EDT

Vivos Inc.

719 Jadwin Avenue
Richland, WA 99352
United States
509-736-4000
https://www.radiogel.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael K. Korenko Ph.D.	CEO, President & Director	266.39k	N/A	1946
Dr. Carlton M. Cadwell D.D.S.	Independent Chairman & Secretary	N/A	N/A	1945
Mr. Michael H. Pollack CPA	Chief Financial Officer	N/A	N/A	1966
Dr. David J. Swanberg M.S., P.E.	Chief Operating Officer	N/A	N/A	1957
Dr. Fu-Min Su	Chief Radio Chemist & Radiation Safety Officer	98.65k	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

Corporate governance

Vivos Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.